|
End-of-day quote
Korea S.E.
23/09/2026
|
5-day change | 1st Jan Change | ||
| 8,180.00 KRW | +12.21% |
|
+16.86% | +19.94% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 26/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 27/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 29/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 30/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +12.21% | +16.86% | +2.51% | - | 142M | ||
| +4.61% | +11.60% | +149.40% | +792.16% | 56.33B | ||
| +1.63% | -4.27% | +10.60% | +50.60% | 24.65B | ||
| -0.69% | -2.39% | -12.73% | -38.69% | 6.62B | ||
| -2.60% | -8.32% | -5.60% | +158.28% | 5.76B | ||
| +1.92% | +1.90% | +18.71% | +67.66% | 3.36B | ||
| +3.85% | -15.69% | -22.54% | +2,364.62% | 2.54B | ||
| +6.54% | -1.66% | +148.54% | +60.99% | 2.36B | ||
| +17.77% | +2.56% | +35.30% | +47.85% | 2.32B | ||
| +1.10% | +8.21% | -0.81% | -52.89% | 1.98B | ||
| Average | +4.63% | +0.54% | +32.34% | +383.40% | 10.61B | |
| Weighted average by Cap. | +3.37% | +5.16% | +84.83% | +499.56% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















